Pharming announces public cash offer to the shareholders of Abliva AB
15 déc. 2024 13h45 HE
|
Pharming Group N.V.
Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim...
Pharming announces positive topline data in pediatric clinical trial of leniolisib
11 déc. 2024 01h00 HE
|
Pharming Group N.V.
Multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Data consistent with the improvements seen in the previously...
Pharming Group to participate in November investor conference
05 nov. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports third quarter 2024 financial results and provides business update
24 oct. 2024 01h00 HE
|
Pharming Group N.V.
Third quarter 2024 total revenues increased by 12% to US$74.8 million, compared to the third quarter 2023, driven by continued strong RUCONEST® and Joenja® revenue growthRUCONEST® third quarter...
Pharming Group to report third quarter 2024 financial results on October 24
10 oct. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial...
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
10 oct. 2024 01h00 HE
|
Pharming Group N.V.
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes PIDs to include ALPS-FAS, CTLA4 haploinsufficiency, NFKB1...
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
26 sept. 2024 01h00 HE
|
Pharming Group N.V.
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the...
Pharming Group to participate in September investor conferences
04 sept. 2024 01h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor...
Pharming Group reports second quarter and first half 2024 financial results and provides business update
01 août 2024 01h00 HE
|
Pharming Group N.V.
Second quarter 2024 total revenues increased by 35% to US$74.1 million, compared to the second quarter 2023, driven by strong RUCONEST® and Joenja® revenue growthRUCONEST® second quarter revenue...
Pharming Group to report second quarter and first half 2024 financial results on August 1
18 juil. 2024 02h00 HE
|
Pharming Group N.V.
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024...